VB 10.16

Drug Profile

VB 10.16

Alternative Names: VB10.16

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaccibody
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Antigen-presenting-cell-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical intraepithelial neoplasia

Most Recent Events

  • 25 Oct 2016 Vaccibody in-licenses needle free injection technology from PharmaJet
  • 01 Mar 2016 Vaccibody completes enrolment in its phase I trial for Cervical intraepithelial neoplasia in Germany (NCT02529930)
  • 13 Sep 2015 Phase-I/II clinical trials in Cervical intraepithelial neoplasia in Germany (IM) (NCT02529930)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top